Human CYPs involved in drug metabolism: structures, substrates and binding affinities

Importance of the field: There is current interest in the CYPs primarily due to their important role in the Phase I metabolism of foreign compounds, including pharmaceuticals, agrochemicals and environmental pollutants, to which mankind is exposed. Areas covered in this review: The roles of the human CYPs are introduced in the context of using structural modelling and quantitative structure–activity relationships for rationalising substrate binding, selectivity and rates of metabolism, particularly for drugs in current clinical use. The importance of compound lipophilicity in both substrate binding and metabolic rate is emphasised, together with the employment of an automated docking method (AutoDock) for estimating binding energy and likely route of metabolism for drug substrates. What the reader will gain: The location of key interacting groups on both substrate and enzyme tends to define the preferred outcome of CYP-mediated drug metabolism in the majority of cases investigated thus far. This enables one to draw up a simple model of the important features present in the binding sites of CYPs which relate to substrate selectivity and likely positions of metabolism. Take home message: For the major CYPs involved in human drug metabolism, it would appear that there is a relatively well-defined key distance, in terms of number of intervening atoms, between the main sites of binding and CYP-mediated metabolism.

[1]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[2]  G. Loew,et al.  Homology modeling and substrate binding study of human CYP2C9 enzyme , 1999, Proteins.

[3]  D. Lewis,et al.  Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. , 2008, Expert opinion on drug metabolism & toxicology.

[4]  Yuko Ito,et al.  Chapter 1:Cytochrome P450 Structure and Function: An Evolutionary Perspective , 2008 .

[5]  D. Lewis,et al.  Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. , 2006, Current drug metabolism.

[6]  Laura Lowe Furge,et al.  Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction , 2006, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[7]  J. M. Pratt,et al.  The P450 catalytic cycle and oxygenation mechanism. , 1998, Drug metabolism reviews.

[8]  C. Ioannides Cytochromes P450 : role in the metabolism and toxicity of drugs and other xenobiotics , 2008 .

[9]  D. Lewis,et al.  Enzyme-Substrate Binding Interaction Energies and Their Application to the Cytochrome P450 System , 2008 .

[10]  Corwin Hansch,et al.  QSAR of Cytochrome P450 , 2004, Drug metabolism reviews.

[11]  S. Shaik,et al.  Computational Approaches to Cytochrome P450 Function , 2005 .

[12]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[13]  Lars Carlsson,et al.  State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications , 2007, Drug metabolism reviews.

[14]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[15]  M. J. Coon,et al.  Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. , 2003, Archives of biochemistry and biophysics.

[16]  C. Hansch,et al.  QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.

[17]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[18]  S. Ekins,et al.  Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[20]  Gordon C K Roberts,et al.  Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. , 2004, Journal of medicinal chemistry.

[21]  Yuko Ito,et al.  Structural modelling of the human drug-metabolizing cytochromes P450. , 2006, Current medicinal chemistry.

[22]  D. Putt,et al.  AN INCREDIBLY FAST APPARENT OXYGEN REBOUND RATE CONSTANT FOR HYDROCARBON HYDROXYLATION BY CYTOCHROME P-450 ENZYMES , 1995 .

[23]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[24]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[25]  Yuko Ito,et al.  Analysis of CYP2D6 substrate interactions by computational methods. , 2008, Journal of molecular graphics & modelling.

[26]  M. Levitt,et al.  Aromatic Rings Act as Hydrogen Bond Acceptors , 2022 .

[27]  Slobodan Petar Rendic Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[28]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[29]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[30]  F. Guengerich,et al.  Substrate binding to cytochromes P450 , 2008, Analytical and bioanalytical chemistry.

[31]  F. Guengerich Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.

[32]  G H Loew,et al.  Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes , 1999, Proteins.

[33]  D. Lewis,et al.  57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.

[34]  D. Lewis Guide to Cytochromes P450 : structure and function , 2001 .

[35]  D. Lewis,et al.  Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: The importance of compound lipophilicity , 2007, Journal of enzyme inhibition and medicinal chemistry.

[36]  Stewart B Kirton,et al.  In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[37]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[38]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[39]  D. Lewis,et al.  Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. , 2003, Current medicinal chemistry.

[40]  D. Lewis,et al.  Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  D. Lewis Hydrogen Bonding in Human P450-Substrate Interactions: A Major Contribution to Binding Affinity , 2004, TheScientificWorldJournal.